PL329530A1 - Derivatives of azetidinone for use in treatment of arterial atheromatosis - Google Patents

Derivatives of azetidinone for use in treatment of arterial atheromatosis

Info

Publication number
PL329530A1
PL329530A1 PL97329530A PL32953097A PL329530A1 PL 329530 A1 PL329530 A1 PL 329530A1 PL 97329530 A PL97329530 A PL 97329530A PL 32953097 A PL32953097 A PL 32953097A PL 329530 A1 PL329530 A1 PL 329530A1
Authority
PL
Poland
Prior art keywords
atheromatosis
azetidinone
arterial
derivatives
treatment
Prior art date
Application number
PL97329530A
Inventor
Colin Andrew Leach
Deirdre Mary Bernadette Hickey
Robert John Ife
Dashyant Dhanak
Colin Theobald
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608646.7A external-priority patent/GB9608646D0/en
Priority claimed from GBGB9623756.5A external-priority patent/GB9623756D0/en
Priority claimed from GBGB9625121.0A external-priority patent/GB9625121D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PL329530A1 publication Critical patent/PL329530A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
PL97329530A 1996-04-26 1997-04-15 Derivatives of azetidinone for use in treatment of arterial atheromatosis PL329530A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9608646.7A GB9608646D0 (en) 1996-04-26 1996-04-26 Novel compounds
GBGB9623756.5A GB9623756D0 (en) 1996-11-15 1996-11-15 Novel compounds
GBGB9625121.0A GB9625121D0 (en) 1996-12-03 1996-12-03 Novel compounds

Publications (1)

Publication Number Publication Date
PL329530A1 true PL329530A1 (en) 1999-03-29

Family

ID=27268259

Family Applications (1)

Application Number Title Priority Date Filing Date
PL97329530A PL329530A1 (en) 1996-04-26 1997-04-15 Derivatives of azetidinone for use in treatment of arterial atheromatosis

Country Status (17)

Country Link
EP (1) EP0915843A1 (en)
JP (1) JP2000509049A (en)
AR (1) AR006833A1 (en)
AU (1) AU2698697A (en)
BR (1) BR9709196A (en)
CA (1) CA2252696A1 (en)
CZ (1) CZ341098A3 (en)
HU (1) HUP9901359A3 (en)
ID (1) ID16660A (en)
IL (1) IL126696A0 (en)
MA (1) MA26426A1 (en)
NO (1) NO984939L (en)
NZ (1) NZ332476A (en)
PE (1) PE64398A1 (en)
PL (1) PL329530A1 (en)
TR (1) TR199802160T2 (en)
WO (1) WO1997041098A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229479B1 (en) * 2000-02-16 2014-01-28 Glaxo Group Ltd Pyrimidine-4-one derivatives
NZ527852A (en) 2001-03-28 2005-03-24 Schering Corp Enantioselective synthesis of azetidinone intermediate compounds
ES2275007T3 (en) * 2001-05-25 2007-06-01 Schering Corporation USE OF SUBSTITUTED AZETIDINONE DERIVATIVES IN THE TREATMENT OF ALZEIMER'S DISEASE.
CN105748480A (en) 2007-05-11 2016-07-13 宾夕法尼亚大学理事会 Methods of treatment of skin ulcers
MX2009012188A (en) 2007-05-11 2010-02-24 Univ Jefferson Methods of treatment and prevention of neurodegenerative diseases and disorders.
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
US8637536B2 (en) 2010-12-06 2014-01-28 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
WO2013000267A1 (en) 2011-06-27 2013-01-03 中国科学院上海药物研究所 Azole heterocyclic compound, preparation method, pharmaceutical composition and use
CA2843102A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited Bicyclic pyrimidone compounds
CA2842965A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
BR112015017759B1 (en) 2013-01-25 2022-05-24 Glaxosmithkline Intellectual Property Development Limited LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 INHIBITOR COMPOUNDS (LP-PLA2) BASED ON 2,3-DIHYDROIMIDAZOLE[1,2-C]PYRIMIDIN5(1H)-ONA, AND A PHARMACEUTICAL COMPOSITION COMPRISING SUCH COMPOUNDS
CA2899143A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of lp-pla2
JP2016508995A (en) 2013-01-25 2016-03-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Compound
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN112778331B (en) 2019-11-09 2022-07-05 上海赛默罗生物科技有限公司 Tricyclic dihydroimidazopyrimidinone derivatives, preparation method, pharmaceutical composition and application thereof
CN115304620A (en) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 Pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
WO1993000332A1 (en) * 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
TW223059B (en) * 1991-07-23 1994-05-01 Schering Corp
CA2108584C (en) * 1992-10-27 1998-11-24 James B. Doherty Substituted azetidinones as anti-inflammatory and antidegenerative agents
AU5802894A (en) * 1992-12-17 1994-07-04 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
EP0974663A1 (en) * 1993-06-25 2000-01-26 Smithkline Beecham Plc Lipoprotein associated phospholipase A2, inhibitors thereof and use of same in diagnosis and therapy
US5641669A (en) * 1993-10-06 1997-06-24 Icos Corporation Platelet-activating factor acetylhydrolase
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
MA23834A1 (en) * 1994-12-22 1996-10-01 Smithkline Beecham Plc PROCESS FOR THE PREPARATION OF INHIBITOR COMPOUNDS OF THE LP-PLA2 ENZYME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1996029307A1 (en) * 1995-03-23 1996-09-26 Japan Tobacco Inc. Diphenylmethyl-azetidinone compounds and elastase inhibitor
HUP9901153A3 (en) * 1995-07-01 1999-11-29 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis, their production and pharmaceutical compositions containing them
EP0865429A1 (en) * 1995-12-08 1998-09-23 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis

Also Published As

Publication number Publication date
MA26426A1 (en) 2004-12-20
HUP9901359A2 (en) 1999-08-30
AR006833A1 (en) 1999-09-29
TR199802160T2 (en) 1999-04-21
NO984939L (en) 1998-12-23
NZ332476A (en) 2000-06-23
IL126696A0 (en) 1999-08-17
PE64398A1 (en) 1999-01-06
HUP9901359A3 (en) 2000-03-28
BR9709196A (en) 1999-05-25
CA2252696A1 (en) 1997-11-06
ID16660A (en) 1997-10-30
NO984939D0 (en) 1998-10-23
JP2000509049A (en) 2000-07-18
WO1997041098A1 (en) 1997-11-06
EP0915843A1 (en) 1999-05-19
CZ341098A3 (en) 1999-03-17
AU2698697A (en) 1997-11-19

Similar Documents

Publication Publication Date Title
PL329530A1 (en) Derivatives of azetidinone for use in treatment of arterial atheromatosis
GB9701206D0 (en) Serine derivatives and their use as therapeutic agents
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
GB9518115D0 (en) Triazole derivatives and their use as therapeutic agents
ZA96740B (en) Skin treatment composition
PL318760A1 (en) Spiroazabicyclo compounds useful in medical treatment
PL317930A1 (en) Oxalydine compounds, method of obtaining them and therapeutic agents
PL329440A1 (en) Derivatives of d-proline, method of obtaining them and therapeutic agent containing such compounds
ZA953256B (en) Skin treatment composition
PL320937A1 (en) Substituted azetidin-2-ones for treating arterial atheromatosis
ZA959100B (en) Azetidinone derivatives for the treatment of atherosclerosis
PL321201A1 (en) Derivatives of 4-hydroxypiepridine, method of obtaining them and therapeutic agents containing such derivatives
IL126093A0 (en) Promotion of regeneration of organized tissues
HK1018271A1 (en) Substituted benzylamines and their use for the treatment of depression
EP0835092A4 (en) Composition and treatment for baldness
GB9405021D0 (en) Skin treatment composition
GB9405400D0 (en) Taxane derivatives
HUP0001792A3 (en) Dibenzo-oxazepine and-dioxepine derivatives and their use as anti-tumor agents
PL328795A1 (en) Method of obtaining n-rotected derivatives of d-proline
GB2296239B (en) Taxane derivatives
ZA952120B (en) Skin treatment composition
PL329053A1 (en) Novel derivatives of oxazolydine, method of obtaining them and therapeutic agents containing such compounds
EP0941105A4 (en) Pretraumatic use of hemoglobin
AU2713797A (en) Depigmentating agent in the treatment of melasma
GB9704174D0 (en) Agent for medical treatment